Výsledky vyhledávání - Ludwig Kappos
- Zobrazuji výsledky 1 - 20 z 212
- Přejít na další stránku
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: Application of an extended blood-brain barrier leakage correction Autor Reta Haselhorst, Ludwig Kappos, Deniz Bilecen, Klaus Scheffler, David M�ri, E. W. Rad�, Joachim Seelig
Vydáno 2000Artigo -
10
-
11
-
12
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4<sup>+</sup>T Cells of Patients with Relapsing-Remitting Multiple Sclerosis Autor Maria Meira, Claudia Sievers, Francine Hoffmann, Maria Rasenack, Jens Kühle, Tobias Derfuß, Ludwig Kappos, Raija L.P. Lindberg
Vydáno 2014Artigo -
13
-
14
-
15
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results Autor Helmut Butzkueven, Ludwig Kappos, Fabio Pellegrini, María Trojano, Heinz Wiendl, Ruchi Patel, A. Zhang, Christophe Hotermans, Shibeshih Belachew
Vydáno 2014Artigo -
16
-
17
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. Autor A Valli, Alessandro Sette, Ludwig Kappos, Carla Oseroff, John Sidney, G Miescher, Martina Hochberger, Eliseo Albert, Luciano Adorini
Vydáno 1993Artigo -
18
Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM st... Autor Eva Havrdová, Gavin Giovannoni, Ralf Gold, Robert Fox, Ludwig Kappos, J. Theodore Phillips, Macaulay Okwuokenye, Jing L. Marantz
Vydáno 2017Artigo -
19
-
20
Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE Autor Ralf Gold, Douglas L. Arnold, Amit Bar‐Or, Robert J. Fox, Ludwig Kappos, Chongshu Chen, Becky Parks, Catherine Miller
Vydáno 2020Artigo
Vyhledávací nástroje:
Související témata
Medicine
Multiple sclerosis
Internal medicine
Immunology
Pathology
Psychiatry
Radiology
Magnetic resonance imaging
Biology
Alternative medicine
Placebo
Gastroenterology
Neuroscience
Expanded Disability Status Scale
Fingolimod
Psychology
Disease
Adverse effect
Clinical trial
Confidence interval
Physical therapy
Cohort
Biochemistry
Clinically isolated syndrome
Randomized controlled trial
Pediatrics
Natalizumab
Oncology
Gene
Genetics